Abstract: Provided are methods for increasing platelet response in a subject at risk for bleeding due at least in part to a low platelet count by administering to a subject with a low platelet count an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridine-2-yl)piperidine-4-carboxylic acid.

Abstract: The invention features methods and kits for treating an immunoinflammatory disorder, by administering to a patient diagnosed with or at risk of developing such immunoinflammatory disorder an adenosine activity upregulator in combination with one or more additional agents.

Abstract: The invention features methods, compositions, and kits for treating a musculoskeletal disorder, e.g., osteoarthritis, or pain, fatigue, tenderness, impairment in mobility, soft tissue swelling, or bony swelling associated therewith, by administering to a patient diagnosed with or at risk of developing such pain, fatigue, tenderness, impairment in mobility, soft tissue swelling, or bony swelling a tetra-substituted pyrimidopyrimidine, e.g., dipyridamole, or an adenosine activity upregulator, in combination with one or more additional agents. The invention further features methods, compositions, and kits for treating a patient diagnosed with or at risk of developing a musculoskeletal disorder by administering to the patient a tetra-substituted pyrimidopyrimidine or an adenosine activity upregulator in combination with one or more additional agents.

Abstract: The invention features methods for identifying new combination therapies for the treatment of cancer and other proliferative diseases.

Abstract: The invention features combinations of drugs for the treatment of proliferative diseases (e.g., cancer). The invention also features methods for identifying new combination therapies for the treatment of cancer and other proliferative diseases.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Abstract: The invention features methods for identifying new combination therapies for the treatment of cancer and other proliferative diseases.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient pentamidine or a pentamidine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.